Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Entera Bio Ltd.NASDAQ: ENTX

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's Mar 2026 deferred revenue of $0 is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.0% of total assets for ENTX, versus a peer median of 0.0%.
ENTX Competitors Peer median
Deferred Revenue for ENTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEERSeer, Inc.Mar 2026$334K -19.1%+36.9%0.1%
ENTXEntera Bio Ltd.Mar 2026$0 ——0.0%
IRDOpus Genetics, Inc.Mar 2026$0 ——0.0%
AGENAgenus Inc.Mar 2026$0 -100.0%-54.7%0.0%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ANIXAnixa Biosciences, Inc.Apr 2026$0 ——0.0%
HURATuHURA Biosciences, Inc.Mar 2026$0 ——0.0%
SPROSpero Therapeutics, Inc.Mar 2026$0 -100.0%-70.8%0.0%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
MCRBSeres Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ENTX) $0-100.0%-54.7%0.0%

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents24.89M12.31M11.02M8.66M7.11M
Short-term Investments00000
Net Receivables183K246K0126K219K
Inventory00000
Other Current Assets254K294K238K186K(219K)
Total Current Assets25.33M12.85M11.26M8.97M7.11M
Property, Plant & Equipment (Net)395K229K488K332K134K
Goodwill00000
Intangible Assets00000
Long-term Investments00080K90K
Tax Assets217K43K14K00
Other Non-current Assets46K6K6K6K(90K)
Total Non-current Assets658K278K508K418K134K
Total Assets25.99M13.13M11.77M9.39M15.99M
Account Payables166K17K83K132K448K
Short-term Debt00000
Tax Payables134K0000
Deferred Revenue15K0000
Other Current Liabilities455K300K500K339K432K
Total Current Liabilities3.16M1.34M1.09M1.18M2.2M
Long-term Debt0000260K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities138K32K32K32K429K
Total Non-current Liabilities261K32K288K134K689K
Total Liabilities3.42M1.37M1.38M1.31M2.89M
Common Stock001K1K1K
Retained Earnings(82.43M)(95.5M)(104.39M)(113.93M)(125.37M)
Accumulated OCI41K41K41K41K41K
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.57M11.75M10.39M8.08M13.1M
Total Debt302K91K390K272K490K
Net Debt(24.59M)(12.22M)(10.63M)(8.39M)(6.62M)

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.